Bharat Book Bureau
Your
one-stop-shop for business information
| About us | |||||||||||||||||||
|
Conference on Colloquium on Obesity Drug
Development
|
|||||||||||||||||||
|
|
||||
|
Dear Colleague, More than one million prescriptions are being written for obesity drugs in the UK alone, costing £47.5m a year and accounting for nearly 3% of total NHS expenditure. If untreated, obesity and related illnesses can cost many times this amount, so there is understandably a large market for drugs to treat the condition. In the last decade the obesity epidemic has increased rapidly both in terms of proportion of the affected population of affected countries, but also in the number of countries where there is a cause for concern. Rather than being confined to a handful of developed nations, the disorder now affects many countries worldwide. If you have not yet taken steps in this direction, or you’d like to know how to improve your chances of securing approval for your new products, our lineup of expert speakers at visiongain’s 2008 Obesity Colloquium will be on hand to share their knowledge and experience. This event promises to bring together leaders in the fi eld, so why not take the time to reserve your place now? However, the market has encountered mixed fortunes in recent years, and lack of adequate reimbursement could foreseeably limit the potential of anti-obesity drugs. By networking with your peers this October, you will fi nd out what steps need to be taken in order to stay competitive, and also to avoid unexpected setbacks. Visiongain’s hotly-anticipated event will enable you to examine the latest technological breakthroughs, discuss and debate scientifi c processes, share expert opinions on all aspects of treatment, and forge the right partnerships for the combating obesity in the coming years Places are limited, so I invite you to book now to avoid missing out on what promises to be a unique exchange of knowledge and ideas. I hope to see you there. Best regards, Andrea Charles Key Themes • Learn
approaches and emerging options for clinical weight
management Who Should Attend? By organisation Pharmaceutical
and Biotechnology Companies By job title Head of Drug
Development Strategy Implementing gene expression based drug response profiling in clinical trials Day 1 COLLOQUIUM ON OBESITY DRUG DEVELOPMENT [MONDAY 13TH OCTOBER 2008] 09:00 Registration and refreshments 09:30 Opening address from the chair Dr. Alina Rodriguez Dept. of Psychology Uppsala University 09:40 Examining patient need and drug development • Obesity and
the impact on patient health Professor John Wilding Head of Diabetes and Endocrinology Research Unit University Hospital University Hospital Aintree 10.20 The clinical positioning of pharmacotherapy for obesity Dr Nick Finer Clinical Director, Wellcome Clinical Research Addenbrooke’s Hospital 11:10 Morning refreshments 11:30 Weight loss surgery for severe obesity - A last resort when drug-based treatments fail • Physiology
of the gastric bypass 12:10 Obesity and type 2 diabetes • What can be
done and to what extent can it be successful? Dr. Karin Rimvall Associate Director, Section for Diabetes and Obesity AstraZeneca 12:50 Networking lunch 14:00 Introduction to obesity and mental health • Adiposity
and the brain Dr. Alina Rodriguez Dept. of Psychology Uppsala University 14:40 Other complaints and their treatment • Avoiding
respiratory difficulties Timothy F
Herpin 15:20
Afternoon refreshments Professor
David J Heal 16:20 Panel discussion: Comparing Germany, the UK, US, Japan, and developing nations • Discussing
the EU Health Commissioner report that more than half of Dr. Matthew
Coghlan* 17:00 Closing remarks from the chair 17:05 Networking drinks Take your discussions further and build new relationships in a relaxed and informal setting. Day 2 COLLOQUIUM ON OBESITY DRUG DEVELOPMENT [TUESDAY 14TH OCTOBER 2008] 09:00 Registration and refreshments 09:30 Opening address from chair 09:40 Old & new examples of
obesity therapy – can we get more effective? 10:20 Acomplia was rejected by FDA Panel in 2007 – Analysing Sanofi-Aventis’
response • How did the anti-obesity market suffer after the withdrawal of Fenfl uramine and Dexfenfl uramine? • Obstacles facing US Approval for Rimonabant casts a shadow over other obesity drugs • Analysing the OTC version of Orlistat. approved in the US and involved in a licensing deal with GSK • Best practices and lessons learned Dr. Krishna Prasad Medicines and Healthcare products Regulatory Agency Department of Health 11:00 Morning refreshments • Will lack of adequate reimbursement limit the potential of anti-obesity drugs? • Reimbursement for
Acomplia - A concern for Sanofi -Aventis? 12:00 Presentation to be
announced • How serious is the
problem? Professor Anthony Kafatos Social Medicine 14:30 Understanding energy intake in the obese and obesogenic behaviour as a pharmacological target • Is there
such as thing as an obesogenic eating style? Dr. Jason C.G. Halford Reader in Appetite and Obesity, Director of the Kissileff Human Ingestive Behaviour Laboratory School of Psychology University of Liverpool 15:10 Afternoon refreshments 15:30 Panel Discussion: Phase 2 trials – a thorough roundup • Novo
Nordisk’s Liraglutide 16:00 Pipeline Developments in anti-obesity Treatments • Genzyme’s GT
389255 Dr. Hubert C.
Chen 16:20 Phase 3 trials – assessing suitability for widespread use • Merck & Co’s
Taranabant Dr John Wick Johnson Director, Licensing & Development Pfizer 17:00 Chair’s closing remarks and end of conference
|
||||
For more information, kindly contact us at :
Bharat Book
Bureau
207, Hermes Atrium, Sector 11, PO
Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail :
info@bharatbook.com
Website :
www.bharatbook.com
|